Skip to main content

Table 1 Characteristics of the studies included in the meta-analysis

From: Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases

First author Year Language Patients source Patients Number Technique Type of patients HR estimation HR(95%CI) of OS HR(95%CI) of RFS
Ghoussoub 1998 English USA 88 IHC BC Given by author 3.47 (1.22-9.90) NA
Camp 1999 English USA 113 IHC LNN BC Given by author 5.05 (1.20-21.30) NA
Nakopoulou 2000 English Greece 43 IHC BC Survival curve 0.14 (0.00-6.41) NA
Ocal 2003 English USA 324 IHC LNN BC Given by author 2.04 (1.26-3.30) NA
Kang 2003 English USA 330 IHC LNN BC Given by author 1.86 (1.19-2.91) NA
Lengyel 2005 English USA 40 IHC LNN BC Given by author NA 3.00 (1.08-8.30)
Chen 2007 English Taiwan 104 IHC Early stage (T1-2N0M0) BC Given by author NA 3.33 (1.67-6.65)
Vendrell 2008 English France 33 RTQ-PCR ER positive BC Given by author 1.08 (0.40-2.88) 1.38 (0.60-3.21)
Ponzo 2009 English Canada 668 IHC LNN BC Given by author NA 1.35 (0.87-2.10)
Liu 2011 Chinese China 106 IHC BC Survival curve 2.41 (0.33-17.71) NA
Gisterek 2011 English Poland 302 IHC BC Survival curve 0.45 (0.22-0.93) NA
Li 2012 Chinese China 100 IHC BC Survival curve 1.6 (0.15-17.49) 1.59 (0.54-4.74)
Raghav 2012 English USA 257 RPPA BC Given by author 2.81 (1.19-6.64) 2.06 (1.08-3.94)
Minuti 2012 English Poland 132 FISH HER-2 positive MBC Given by author 1.12 (0.65-1.93) NA
Gonzalez-Angulo 2013 English USA 970 MIP BC Given by author NA 1.53 (0.98-2.38)
Zagouri 2013 English Austria 170 IHC TNBC Given by author 3.74 (1.65-8.46) 3.43 (1.65-7.12)
Ho-Yen 2014 English UK 1002 IHC BC Given by author 1.85 (1.07-3.19) NA
Inanc 2014 English Turkey 97 IHC TNBC Given by author 1.16 (0.55-2.45) 2.05 (0.96-4.37)
Zagouri 2014 English Austria 78 IHC ER and HER-2 positive BC Given by author 1.32 (0.91-1.90) 1.22 (0.91-1.63)
Koh 2014 English Korea 129 IHC BC Given by author 0.37 (0.16-0.86) 0.65 (0.33-1.26)
Kim 2014 English Korea 924 IHC BC Given by author 1.78 (1.26-2.51) 1.39 (1.08-1.78)
  1. Note: IHC, immunohistochemistry; RT-PCR, Real-time quantitative PCR; RPRP, Reverse phase protein lysate microarray; FISH, Fluorescence in situ hybridization; MIP, Molecular Inversion Probes; BC, breast cancer; MBC, metatastatic breast cancer; TNBC, triple negative breast cancer; LNN, Lymph Node Negative; OS, over survival; RFS, Relapse-free survival; NA, not available